Skip to main content
Equibles

Qube Research & Technologies Ltd

Position in GILD — Gilead Sciences, Inc.

CIK 1729829 LONDON, X0
Back to GILD Full portfolio

Position in GILD

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$16,871,017
-$295,752,427 QoQ
Shares Held
121,052
-95.2% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
23 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in GILD Over Time

Shares Held

Position Value (USD)

Derivatives in GILD

reported options exposure · as of Mar 31, 2026
CallValue
$9,128,735
CallShares
65,500
PutValue
$6,299,524
PutShares
45,200

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

Qube Research & Technologies Ltd holds $1,093,630,705 across 9 Drug Manufacturers - General names. GILD ranks #8 (1.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 715,082 $657,710,971
2 BMY
Bristol Myers Squibb Co
 3,203,665 $194,302,282
3 AZN
Astrazeneca PLC
 382,048 $75,347,506
4 AMGN
Amgen Inc
 147,488 $51,893,652
5 BIIB
Biogen Inc.
 212,921 $39,034,806
6 GSK
GSK plc
 548,222 $30,256,372
7 NVS
Novartis AG
 173,137 $26,446,676
8 GILD
Gilead Sciences, Inc.
This page 		121,052 $16,871,017

All Filings in GILD

Export CSV
44 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $9,128,735 65,500
2026-03-31 $6,299,524 45,200
2026-03-31 $16,871,017 121,052
2025-12-31 $6,566,590 53,500
2025-12-31 $312,623,444 2,547,038
2025-12-31 $8,763,636 71,400
2025-09-30 $535,969,161 4,828,551
2025-09-30 $3,729,600 33,600
2025-09-30 $6,560,100 59,100
2025-06-30 $11,452,871 103,300
2025-06-30 $30,200,988 272,400
2025-06-30 $527,583,210 4,758,575
2025-03-31 $9,703,530 86,600
2025-03-31 $147,838,770 1,319,400
2025-03-31 $264,133,896 2,357,286
2024-12-31 $3,371,505 36,500
2024-12-31 $1,339,365 14,500
2024-09-30 $2,833,792 33,800
2024-09-30 $2,121,152 25,300
2024-06-30 $3,759,828 54,800
2024-06-30 $103,574,547 1,509,613
2024-06-30 $31,526,295 459,500
2024-03-31 $8,599,550 117,400
2024-03-31 $162,076,978 2,212,655
2023-12-31 $1,004,524 12,400
2023-12-31 $19,239,875 237,500
2023-12-31 $57,034,928 704,048
2023-09-30 $13,226,910 176,500
2023-09-30 $3,154,974 42,100
2023-09-30 $86,205,280 1,150,324
2023-06-30 $10,674,195 138,500
2023-06-30 $23,121 300
2023-06-30 $55,624,578 721,741
2023-03-31 $17,966,323 216,540
2022-09-30 $59,910,490 971,154
2022-06-30 $41,525,997 671,833
2022-03-31 $34,045,172 572,669
2021-12-31 $59,013,196 812,742
2021-09-30 $3,587,984 51,367
2021-06-30 $3,787,850 55,008
2021-03-31 $6,062,875 93,809
2020-12-31 $1,501,185 25,767
2020-09-30 $26,693,857 422,438
2020-03-31 $3,908,976 52,287

Report a Problem

Category
Description
Email (optional, for follow-up)